ProfileGDS5678 / 1418932_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 82% 74% 72% 79% 74% 73% 74% 65% 74% 75% 77% 68% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3614470
GSM967853U87-EV human glioblastoma xenograft - Control 26.0266482
GSM967854U87-EV human glioblastoma xenograft - Control 34.8523674
GSM967855U87-EV human glioblastoma xenograft - Control 44.6439272
GSM967856U87-EV human glioblastoma xenograft - Control 55.6011179
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7064674
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6887673
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8193374
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9125665
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8313274
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8915975
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2457277
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1669368
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2004877